Kromann Reumert assisted the Managers in connection with a private placement in Zealand Pharma
Kromann Reumert has assisted the Joint Global Coordinators and Joint Bookrunners and the Co-Managers in connection with the directed issue and private placement of approximately 3.6 million new ordinary shares in Zealand Pharma A/S, yielding gross proceeds to the company of approximately DKK 749 million.
On 27 January 2021, Zealand Pharma A/S ("Zealand") announced the launch of a private placement of new ordinary shares, at a price to be determined through an accelerated book-building process. The private placement was completed on the same date and was priced at DKK 208 per share.
Zealand intends to use the net proceeds to help fund commercialization and pre-launch activities for Zealand's late stage programs, accelerate development of the clinical pipeline, continued support for Zealand’s peptide platform, and for gen-eral corporate purposes.
Kromann Reumert has assisted Goldman Sachs International, Jefferies GmbH and Danske Bank A/S, who acted as Joint Global Coordinators and Joint Bookrunners, and Bryan Garnier & Co. and Nordea Danmark, Filial af Nordea Bank Abp, Finland, who acted as Co-Managers in connection with the accelerated book-building.
Kromann Reumert's core team included Marianne Philip, Christina Bruun Geertsen and Rune Morthorst.
About Zealand
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development, and commercialization of next generation peptide-based medicines that change the lives of people living with metabolic and gastrointestinal diseases. More than 10 drug candidates invented by Zealand have advanced into clinical develop-ment, of which two have reached the market. Zealand’s robust pipeline of investigational medicines includes three candi-dates in late stage development, and one candidate being reviewed for regulatory approval in the United States. Zealand markets V-Go®, an all-in-one basal-bolus insulin delivery option for people with diabetes. License collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals create opportunity for more patients to potentially benefit from Zea-land-invented peptide therapeutics.
Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S., that includes key loca-tions in New York, Boston, and Marlborough (MA).
Contact
